key: cord-1034705-nh1mhaza
authors: Hall, Victoria G.; Ferreira, Victor; Kumar, Deepali; Humar, Atul
title: Impact of immunosuppression on the immune response to SARS‐CoV‐2 infection: A mechanistic study
date: 2021-11-01
journal: Transpl Infect Dis
DOI: 10.1111/tid.13743
sha: 809a0ccb77c01e8951cc8177bbe374d09733c3f9
doc_id: 1034705
cord_uid: nh1mhaza

The optimal management of immunosuppression in transplant patients infected with COVID‐19 is unknown. We performed an in vitro study to determine the effect of individual immunosuppressive agents on SARS‐CoV‐2‐specific T‐cell cytokine expression. Convalescent peripheral blood mononuclear cells from eleven non‐immunosuppressed patients with COVID‐19 were preincubated with clinically relevant concentrations of immunosuppressive drugs (tacrolimus, mycophenolate, sirolimus, prednisone) and then stimulated with a SARS‐CoV‐2 peptide pool. Supernatants were analyzed by 14‐plex high sensitivity T‐cell cytokine array. With increasing concentrations of tacrolimus, there was a trend to reduction in the release of IL‐2 (p = .0137), and IFN‐γ (p = .0147) in response to peptide stimulation. There was also a subsequent trend toward a Th2 phenotype, indicated by lower IFN‐γ:IL‐13 ratio (p = .0663) and IFNγ:IL‐4 ratio (p = .0176). Sirolimus appeared to be associated with a proinflammatory cytokine release, including TNF‐α (p = .0027) and IL‐1β (p = .0016), in response to SARS‐CoV‐2 peptides. In contrast, mycophenolate and prednisone did not influence the SARS‐CoV‐2‐specific cytokine response. These are preliminary findings only, with larger studies required to inform clinical recommendations.

Coronavirus disease 2019 , caused by the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has had significant impact on solid organ transplantation; with mortality rates in transplant recipients ranging from 10% to 20%. 1,2 SARS-CoV-2 is a spherical, single-stranded RNA beta-coronavirus, composed of four structural proteins including the spike glycoprotein (S), membrane (M), envelope (E), and nucleocapsid protein (N) that binds viral RNA. [2] [3] [4] The transition to adaptive immune response is crucial to the clinical progression of SARS-CoV-2 infection. 1 A protective response is T-cell dependent; with CD4 + T lymphocytes helping B cells to produce specific neutralizing antibodies, and cytotoxic CD8 + cells capable of eliminating infected cells with minimal tissue damage. 1 Overall, current data show that both CD4 + T-cell and CD8 + T-cell responses occur in most patients infected by SARS-CoV-2 within 1-2 weeks after symptom onset and are skewed toward the production of mainly T-helper 1 (Th1) cytokines; namely interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), interleukin-2 (IL-2), and a subsequent Th1 immune response. 2 This is in contrast to a dysfunctional immune response, characterized by uncoordinated or partially neutralizing antibodies, uncontrolled viral replication, and elimination of infected cells, which may result in an exacerbated inflammatory response and eventual cytokine storm, acute respiratory distress syndrome and multiorgan dysfunction. 1, 2 In contrast to other respiratory viruses, there is significant induction of proinflammatory cytokines. Severe COVID-19 has been associated with high IL-2R, interleukin-6 (IL-6), interleukin-10 (IL-10), and TNF-α serum levels with conflicting data on interleukin-1 β (IL-1β), interleukin-7 (IL-7), interleukin-8 (IL-8), interleukin-17 (IL-17), IFN-γ, and granulocyte-macrophage colony-stimulating factor (GM-CSF). [5] [6] [7] [8] In transplant patients with acute COVID-19 infection, a major unanswered clinical question is how to adjust immunosuppression.

Decisions around immunosuppression are often formulated based on patient symptoms, the risk of rejection and estimation of how to improve patient outcomes. Reduction in calcineurin inhibitors or antimetabolite doses is performed in order to enhance immune responses, but there are minimal data to guide decisions. 3, 9, 10 We performed an in vitro study to determine the effect of clinically relevant, differing concentrations of individual immunosuppressive agents (tacrolimus, mycophenolate, sirolimus, and prednisone) on SARS-CoV-2-specific T-cell cytokine expression.

A total of 1890 cytokine measurements were performed after stimu- Figure 1 shows the experimental layout. TNFα. Cytokine production was expressed in pg/ml. The quantification limit (QL) was 0.15 pg/ml for IFN-γ, 0.10 pg/ml for IL-2, 0.06 pg/ml for IL-6, 0.11 pg/ml for TNF-α, 0.12 pg/ml for IL-1β and 0.33 pg/ml for IL- 10 . For the purposes of statistical analysis, values below the QL were given a value of half the QL.

For 

PBMCs stimulation with SARS-CoV-2 peptides resulted in broad cytokine responses in the context of differing concentrations of the standard immunosuppressive agents. All positive controls were sig-nificantly and appropriately induced for each cytokine response. Figure 2A and B shows IFN-γ and IL-2 release, respectively, for the 11 participants plotted against differing concentrations of tacrolimus. There was a trend to reduction in IFN-γ release in the presence of tacrolimus (p = .0147). A similar finding was observed for IL-2 release with tacrolimus (p = .0137). IFN-γ and IL-2 release for tacrolimus, mycophenolate, sirolimus, and prednisone is displayed in Table S2 .

Sirolimus was found to be associated with a proinflammatory cytokine release in response to SARS-CoV-2 peptides; including IL-1β (p = .0016), TNF-α (p = .0027), with a possible trend with GM-CSF (p = .0143). There was no significant association with IL-6 (p = .1968). Table S2 ).

Of these, only IL-17 and IL-8 appeared to respond to stimulation with SARS-CoV-2 peptides compared with the negative control of PBMCs alone.

Based on the hypothesis that a predominant Th1 cytokine response is important in a protective immune response to SARS-CoV-2 infection, we analyzed two separate Th1:Th2 ratios: IFN-γ:IL-13 ratio and IFN-γ:IL-4 ratio ( Figure 4A and B, respectively). 16, 17 In the presence of higher concentrations of tacrolimus, there was a possible trend toward a Th2 phenotype as indicated by a reduced IFN-γ: IL-13 ratio (p = .0663) and IFN-γ: IL-4 ratio (p = .0176) when compared to the baseline response without immunosuppression (PBMCs + SARS-CoV-2 peptides).

Given the importance of significant induction of proinflammatory cytokines associated with COVID-19 infection, in particular, the proinflammatory state observed in severe COVID-19, we analyzed the proinflammatory cytokines TNF-α, IL-1β, and IL-6 as a ratio to IL-10 (anti-inflammatory cytokine) expression, to assess proinflammatory to anti-inflammatory cytokine release and how it is affected by immunosuppression ( Figure 5A-C) . Ten participants were included in this Table 2 ).

Our study provides novel preliminary insights into the SARS-CoV- Tacrolimus competitively binds to calcineurin and inhibits the translocation of transcription factors, leading to reduced transcrip-tional activation of cytokine genes, including IL-2 and IFN-γ, among others. 19 Ultimately, the proliferation of T lymphocytes is reduced. 10, 19 There was a trend toward reduction in IL-2 and IFN-γ release in our study and a Th2 phenotype in the presence of increasing concentrations of tacrolimus; however, these did not reach statistical significance. Although trough concentrations in SOT are generally kept under 15 ng/ml, a 2-h postdose level of >20 ng/ml can be achieved and has been suggested to be a better correlate for toxicity and efficacy. 14 The production of IFN-γ by activated T lymphocytes stimulates innate macrophage-mediated immunity and is critical in the immune response to SARS-CoV-2. 22, 23 The importance of both of these cytokines in the immunopathogenesis of COVID-19 highlights the delicate balance required in a regulated cytokine response, which is seen to enhance pathogen clearance but potentially is attached to an increased risk of immunopathology. 24 In response to SARS-CoV-2 peptides, we unexpectedly observed that sirolimus was significantly associated with a proinflammatory from tacrolimus and prednisone, which are both able to inhibit the production of cytokines. 19 Therefore, we may be witnessing unchecked cytokine release in response to SARS-CoV-2 stimulation rather than a specific effect related to sirolimus. The other potential reason is drug toxicity, which has been observed at higher concentrations of sirolimus.

However, the concentrations we used are well within trough and peak concentrations commonly seen in transplant patients. 25 There was a suggested trend toward the inhibition of Th1 responses with greater concentrations of tacrolimus, whereas sirolimus was associated with an unexpected proinflammatory response, and mycophenolate was neutral. Our research is hypothesis generating and descriptive; translation to clinical recommendations, including dose reduction of specific immunosuppressive agents requires further study with a larger sample size.

Immune response, inflammation, and the clinical spectrum of COVID-19

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

COVID-19 in solid organ transplant: a multi-center cohort study

A glimpse into the origins of genetic diversity in the severe acute respiratory syndrome coronavirus 2

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

COVID-19: consider cytokine storm syndromes and immunosuppression

Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China

Clinical and immunological features of severe and moderate coronavirus disease 2019

American Society of Transplantation. 2019-nCoV (coronavirus): FAQs for organ transplantation

COVID-19 pneumonia in kidney transplant recipients: focus on immunosuppression management

Comparison of the effect of standard and novel immunosuppressive drugs on CMVspecific T-cell cytokine profiling

Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients

Inhibition of polyomavirus BK-specific T-cell responses by immunosuppressive drugs. Transplantation

Relationship between 2-hour tacrolimus concentrations and clinical outcomes in long term kidney transplantation

Differences in CMV-specific Tcell levels and long-term susceptibility to CMV infection after kidney, heart and lung transplantation

Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

Broad and strong memory CD4(+) and CD8(+) T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

Dexamethasone in hospitalized patients with COVID-19-preliminary report

Immunosuppressive drugs for kidney transplantation

Systematic examination of antigen-specific recall T cell responses to SARS-CoV-2 versus influenza virus reveals a distinct inflammatory profile

IL-2: the first effective immunotherapy for human cancer

Direct antiviral mechanisms of interferon-gamma

Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic

Integrated immune dynamics define correlates of COVID-19 severity and antibody responses

Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus

Impact of Immunosuppression on the Immune Response to SARS-CoV-2 Infection: A Mechanistic Study

The authors would like to acknowledge Matthew Ierullo and Terrance Ku for their assistance with the laboratory aspects of the study. The study was funded by the Ajmera Transplant Centre.

DK has received advisory board fees from Pfizer. AH has received hon-